Caprion Pharmaceuticals Announces Expansion of Biomarker Discovery Collaboration with Vertex Pharmaceuticals
Montreal, Canada - October 25, 2006 - Caprion Pharmaceuticals Inc.'s Applied BioMedicine group today announced an expansion of a previously established biomarker research collaboration with Vertex Pharmaceuticals Incorporated. The initial collaboration with Vertex was announced in March 2006. The expanded collaboration announced today will continue to apply Caprion's CellCarta® proteomics biomarker technology across preclinical and clinical development activities being conducted by Vertex.
"We believe this expanded collaboration reflects the interest of biotechnology companies to integrate biomarker discovery efforts into major drug development programs," noted Dr. Daniel Chelsky, Executive Vice-President and Chief Scientific Officer at Caprion. "Caprion is pleased with the progress made under the original collaboration with Vertex, and we look forward to further broadening the collaboration in the coming months."
Caprion's proprietary proteomics platform comprehensively profiles proteins and provides an unprecedented level of protein expression and identification in tissues and blood plasma. Caprion is presently conducting biomarker discovery programs in other indications for several pharmaceutical and biotechnology companies and its own clinical programs.
About Caprion Pharmaceuticals Inc.
Caprion Pharmaceuticals Inc. is a clinical-stage biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. The Company's clinical-stage programs include Shigamabs®, a product for the treatment of Shigatoxin-producing bacterial infections, and CAP-232, a targeted therapy with potential efficacy in multiple oncology indications. CellCarta®, Caprion's proprietary proteomics technology, provides Caprion with an effective means to identify novel drug targets, predict which therapeutics may be safer and more efficacious, and identify which patients may benefit most from a particular therapy.
FOR MORE INFORMATION CONTACT:
Caprion Pharmaceuticals Inc.